Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation

Autor: Kyunghye Bang, Andrea Casadei‐Gardini, Changhoon Yoo, Massimo Iavarone, Min‐Hee Ryu, Sook Ryun Park, Hyung‐Don Kim, Young‐In Yoon, Dong‐Hwan Jung, Gil‐Chun Park, Chul‐Soo Ahn, Deok‐Bog Moon, Shin Hwang, Ki‐Hun Kim, Gi‐Won Song, Chiara Mazzarelli, Eleonora Alimenti, Stephen L. Chan, Massimo De Giorgio, Baek‐Yeol Ryoo, Sung‐Gyu Lee
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Cancer Medicine, Vol 12, Iss 3, Pp 2572-2579 (2023)
Druh dokumentu: article
ISSN: 2045-7634
DOI: 10.1002/cam4.5123
Popis: Abstract Introduction Lenvatinib is approved for the treatment of patients with metastatic or recurrent hepatocellular carcinoma (HCC); however, clinical outcomes of lenvatinib therapy in patients with post‐liver transplantation (LT) HCC recurrence remain unclear. We investigated the efficacy and safety of lenvatinib in patients with post‐LT HCC recurrence. Methods This multinational, multicenter, retrospective study included 45 patients with recurrent HCC after LT who received lenvatinib at six institutions in three countries (Korea, Italy, and Hong Kong) from June 2017 to October 2021. Results At the time of lenvatinib initiation, 95.6% (n = 43) of patients had Child–Pugh A status, and 35 (77.8%) and 10 (22.2%) participants were classified as having albumin–bilirubin (ALBI) grades 1 and 2, respectively. The objective response rate was 20.0%. With a median follow‐up duration of 12.9 months (95% confidence interval [CI]: 11.2–14.7), the median progression‐free survival and overall survival (OS) were 7.6 (95% CI: 5.3–9.8) months, and 14.5 (95% CI: 0.8–28.2) months, respectively. Patients with ALBI grade 1 showed significantly better OS (52.3 months, [95% CI: not assessable]) than patients with ALBI grade 2 (11.1 months [95% CI: 0.0–30.4 months], p = 0.003). The most common adverse events were hypertension (n = 25, 55.6%), fatigue (n = 17, 37.8%), and anorexia (n = 14, 31.1%). Conclusion Lenvatinib showed consistent efficacy and toxicity profiles in patients with post‐LT HCC recurrence that were comparable to those reported from previous studies among non‐LT HCC patients. The baseline ALBI grade correlated with better OS in post‐LT lenvatinib‐treated patients.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje